Peanut Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Antihistamines, Epinephrine, Immunotherapies, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F

Market Overview

Global Peanut Allergy Treatment Market was valued at USD 586.10 million in 2024 and is expected to reach USD 1210.20 million by 2030 with a CAGR of 12.84% during the forecast period. This growth is accounted for by the increasing awareness of peanut allergy, and advances in technology. Peanut allergy is a serious and potentially life-threatening condition affecting millions of people worldwide. The Peanut Allergy Treatment Market has been growing rapidly in recent years due to the increasing prevalence of peanut allergy and the need for effective treatment options. Advances in research have led to a better understanding of the mechanisms underlying peanut allergy, which has enabled the development of more targeted and effective treatments. For example, the development of allergen-specific immunotherapy and gene therapies would not have been possible without advances in biotechnology and genetic engineering.

Many pharmaceutical companies and research institutions have recognized the potential of the peanut allergy treatment market and are investing heavily in developing new treatments through research and development.

Key Market Drivers

Rising Prevalence of Peanut Allergies

The increasing prevalence of peanut allergies globally is a significant driver for the growth of the peanut allergy treatment market. In Western countries, the incidence of peanut allergy has risen substantially over the past two decades. For instance, in the United States, the prevalence among children increased from 0.4% in 1997 to 1.4% in 2008, representing a 3.5-fold increase. Similarly, in the United Kingdom, food allergies in children under five have more than tripled from 1.2% to 4% between 2008 and 2018.​

This surge in peanut allergy cases has led to heightened demand for effective treatments and management strategies. Governments and health organizations have recognized the growing public health concern. For example, the U.S. Centers for Disease Control and Prevention (CDC) has reported a significant increase in food allergy prevalence among children, emphasizing the need for improved diagnostic tools and therapeutic options. The rising awareness and concern among parents, coupled with the potential severity of allergic reactions, has further propelled the demand for innovative treatments.​

Consequently, pharmaceutical companies are investing in research and development to create effective therapies, including immunotherapies and biologics, to address this growing health issue. The combination of increasing prevalence and heightened awareness underscores the critical need for advancements in peanut allergy treatments, driving market growth.

Increased Investment in Research and Development

Significant investments in research and development (R&D) are propelling the growth of the peanut allergy treatment market. These investments focus on advancing immunotherapies, desensitization techniques, and diagnostic tools to manage and potentially cure peanut allergies. For example, Aravax's PVX108 immunotherapy has received Phase 2 trial approvals from both the U.S. FDA and Australia's Therapeutic Goods Administration, highlighting the global commitment to developing effective treatments.​

Government initiatives play a crucial role in supporting R&D efforts. In addition to the Victorian Government's investment, other countries are implementing policies to encourage innovation in allergy treatments. These policies include funding grants, tax incentives, and streamlined regulatory pathways for promising therapies. Such support accelerates the development and commercialization of new treatments, addressing the growing demand for effective peanut allergy management options.​

Download Free Sample Report

Key Market Challenges

High Cost of Treatment

The high cost of peanut allergy treatments poses a significant challenge to market growth and patient access. Immunotherapy and biologic treatments often involve substantial expenses, including the cost of the therapy itself, administration, monitoring, and potential side effects management. These costs can be prohibitive for many patients, particularly in regions with limited healthcare coverage or reimbursement options.​

Insurance coverage for peanut allergy treatments varies widely, with some plans offering limited or no reimbursement for newer therapies. This financial burden may deter patients from pursuing potentially beneficial treatments, leading to suboptimal management of their condition. Additionally, the high cost of treatment can strain healthcare systems, especially in countries with publicly funded healthcare programs.​

Addressing the affordability of peanut allergy treatments requires collaborative efforts from stakeholders, including pharmaceutical companies, insurers, and policymakers. Strategies such as value-based pricing, patient assistance programs, and policy reforms aimed at improving coverage can help mitigate the financial barriers to accessing effective therapies.

Limited Access to Specialized Care

Access to specialized care for peanut allergy management remains limited in many regions, hindering timely diagnosis and treatment. A shortage of allergists and immunologists, particularly in rural or underserved areas, can lead to delays in identifying and managing peanut allergies. This gap in care may result in increased risk of severe allergic reactions and reduced quality of life for affected individuals.​

Furthermore, disparities in healthcare infrastructure and resources contribute to unequal access to advanced treatments and diagnostic tools. Patients in low- and middle-income countries may face significant challenges in obtaining specialized care, including limited availability of approved therapies and lack of awareness among healthcare providers.​

Efforts to improve access to specialized care include expanding telemedicine services, increasing training opportunities for healthcare professionals, and implementing public health initiatives to raise awareness about peanut allergies.

Key Market Trends

Emergence of Novel Immunotherapies

The development of novel immunotherapies is a prominent trend in the peanut allergy treatment market. These therapies aim to desensitize patients to peanut allergens, reducing the severity of allergic reactions. One notable example is Palforzia, the first FDA-approved oral immunotherapy for peanut allergy, designed to mitigate allergic responses, including anaphylaxis, in children aged four to 17.​

Advancements in immunotherapy are not limited to oral treatments. Researchers are exploring various delivery methods, including sublingual and epicutaneous (skin patch) immunotherapies, to improve patient compliance and outcomes. These innovative approaches offer the potential for more personalized and effective treatment options, catering to the diverse needs of peanut allergy patients.​

The growing pipeline of immunotherapy candidates reflects the market's commitment to addressing the unmet needs of individuals with peanut allergies. As these therapies progress through clinical trials and receive regulatory approvals, they are expected to significantly impact the standard of care for peanut allergy management.

Integration of Biologic Therapies

The integration of biologic therapies into peanut allergy treatment represents a significant advancement in the field. Biologics, such as monoclonal antibodies, target specific components of the immune system involved in allergic reactions. For instance, Xolair (omalizumab), initially approved for asthma, has shown promise in reducing allergic responses to multiple food allergens, including peanuts.​

The adoption of biologic therapies offers several advantages, including the potential for long-lasting effects and the ability to treat patients with severe or multiple allergies. These therapies can be used alone or in combination with traditional immunotherapies to enhance efficacy and safety. Ongoing research aims to identify new biologic targets and develop treatments that provide durable protection against peanut-induced allergic reactions.​

The growing interest in biologic therapies underscores the market's focus on innovative solutions to improve the quality of life for individuals with peanut allergies. As more biologics receive regulatory approvals and become available to patients, they are expected to play an increasingly important role in comprehensive allergy management strategies.

Segmental Insights

Service Insights

Based on drug class, antihistamines have held the largest market share in the global peanut allergy treatment market. This dominance can be attributed to their widespread availability, ease of use, and immediate effectiveness in managing mild to moderate allergic reactions. Antihistamines work by blocking histamine, a chemical released by the immune system during allergic reactions, which helps alleviate symptoms such as itching, swelling, hives, and nasal congestion. Their over-the-counter status in many countries makes them accessible to a broad population, allowing individuals to manage allergy symptoms without needing specialized prescriptions or clinical intervention. This convenience and affordability have made antihistamines a first-line treatment choice for allergic reactions, including those triggered by peanuts.

Download Free Sample Report

Regional Insights

Based on the region, North America holds a prominent position in the global peanut allergy treatment market, accounting for the largest market share. This dominance can be attributed to several factors that create a favorable environment for the development and adoption of advanced allergy treatments. The region benefits from a well-established healthcare infrastructure, widespread awareness of food allergies, and strong presence of leading pharmaceutical and biotechnology companies actively involved in developing and commercializing innovative therapies.

Furthermore, regulatory support and proactive public health initiatives across countries like the United States and Canada contribute to early diagnosis and access to specialized care. The U.S. Food and Drug Administration (FDA), in particular, plays a pivotal role in fast-tracking approvals for breakthrough therapies, ensuring that patients receive timely access to new treatment options. In addition, high healthcare spending and strong insurance coverage in many parts of North America facilitate the adoption of high-cost immunotherapies and biologic treatments, which are crucial for managing severe allergies.

Recent Developments

• In February 2024, Novartis announced the U.S. FDA approval of Xolair (omalizumab), a first treatment for paediatric patients and adults with one or more food allergies including anaphylaxis.
• In December 2024, DBV Technologies SA achieved a key milestone with the FDA for its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has provided an Accelerated Approval pathway for the therapy, streamlining the regulatory process for peanut allergy treatment.
• In November 2023, Aimmune Therapeutics, Inc. announced the U.S. FDA approval of PALFORZIA for use in patients of age 4-17 with peanut allergy. PALFORZIA is indicated for use in combination with a peanut-avoidant diet.

Key Market Players

• Vedanta Biosciences, Inc.
• Alladapt Immunotherapeutics, Inc.
• Regeneron Pharmaceuticals Inc.
• Aravax Pty Ltd
• Teva Pharmaceutical Industries Limited
• Prota Therapeutics Pty Ltd.
• Aimmune Therapeutics, Inc. (Nestle)
• DBV Technologies SA
• Sanofi SA
• Mylan N.V.

Report Scope:

In this report, the Global Peanut Allergy Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Peanut Allergy Treatment Market, By Drug Class:

o   Antihistamines

o   Epinephrine

o   Immunotherapies

o   Others

• Peanut Allergy Treatment Market, By Route of Administration:

o   Oral

o   Intravenous

o   Others

• Peanut Allergy Treatment Market, By Distribution Channel:

o   Retail Pharmacies

o   Hospital Pharmacies

o   Online Pharmacies

• Peanut Allergy Treatment Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Peanut Allergy Treatment Market.

Available Customizations:

Global Peanut Allergy Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Peanut Allergy Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com